Transcript The Norwegian Life Science Industry

The Norwegian Life Science Industry
– a brief presentation
Ole J. Marvik, PhD
Sector coordinator, Biotechnology and Health
Innovation Norway
Technology transfer – practices, opportunities
and challenges.
A seminar during the visit of Dr. Mark L. Rohrbaugh, NIH
Oslo 22 June 06
Biotech; a key technology for Norway
Biomedicine:
i) Diagnostics (GE Healthcare, Axis-Shield,
Diagenic, Nordiag)
ii) Therapeutics (Alpharma, Photocure, Algeta,
Clavis, Affitech, Bionor)
The bluegreen sector:
i) Fish vaccine and breeding (IntervetNorbio, Aquagen, Geno)
ii) Bioprospecting (Pronova Biocare,
Biotec Pharmacon, Biosergen)
Oil/gas and environment:
i) Pollution surveillance (Biosense)
ii) Waste water treatment (AnoxKaldnes Statoil
Mongstad,)
Norwegian life science companies
Human Biobanks
4
Bioinformatics
4
22
Drug discovery & development
4
Drug delivery
15
Medical diagnostics
4
Pharmaceutical
Biomanufacturing
5
10
Tools and reagents
9
Environmental and energy
16
Nutrients
14
Feed
7
Live-stock and fish breending
Aquaculture-related medicine
2
A total of 110 companies employing close to 5000 people and generating a
revenue of NOK 12 billion (2004).
INGREDIENTS, FOOD, FEED
BIOMEDICINE
BIOMEDICINE
AGRO AND AQUACULTURE SUPPORT INDUSTRY
PROCESSING
INDUSTRY, ENERGY,
ENVIRONMENT
OTHERS
Tools and reagents
Drug discovery
Human biobanks
Aqua medicine
Nutients
Environmental
Affitech AS
Cryosave Nordic AS
Intervet Norbio AS
Advanced Biopolymers AS
Anoxkaldnes AS
Biomolex AS
Algeta AS
GeNova AS
Pharmaq AS
Aminotech AS
Biosense Laboratories AS
Dynal Biotech ASA
Avexxin AS
Genova CNS AS
Aqua breeding
Biolink Group
Carrotech AS
Kinn Therapeutics AS
A-viral ASA
(Biobanks for Health)
Aquagen AS
BioSea Management AS
M-lab Mat og Miljø AS
Lingvitae Genomics AS
Bionor Immuno AS
(Norwegian Cancer Registry)
Genomar AS
Calanus AS
Norsk Matanalyse
Cgene AS
Biosergen AS
Medical diagnosis
Genova Aqua AS
Denomaga Nutritional Lipids AS
Norwegian Veritas
Polypure AS
Biotec Pharmacon ASA
Axis-Shield ASA
Live-stock breeding
Firmenich Bjørge Biomarin AS
Statoil Mongstad
Predichem AS
Clavis Pharma AS
Biodetect AS
Bovibank AS
FMC Biopolymer
Toslab AS
Qiagen AS
Drug Discovery Laboratory
Bionor AS
Cryogenetics AS
Natural ASA
Energy
Synthetica AS
Dynal Biotech ASA
Colifast AS
Geno
Napro Pharma AS
Hydro
Vitas AS
FMC Biopolymer
Diagenic AS
Norsvin
Nutri Pharma ASA
Paint
Bioinformatics
GemVax AS
Genpoint AS
Feed
Olivita AS
Nordox Industrier AS
Interagon AS
Lauras AS
Lifecare AS
Akva-Ren AS
ProBio Group AS
Biomanufacturing
Pubgene AS
Lytix Biopharma AS
Norchip AS
Aquapro AS
Pronova Biocare AS
Biosentrum AS
Scencel Bioinformatics AS
Navamedic AS
NorDiag AS
Biomar AS
Seagarden AS
Diatec AS
Molmine AS
Orthogenics AS
Optomed AS
Biotec Pharmacon ASA
Vikholmen Biomarine AS
Norferm AS
Miscellaneous
Photocure ASA
Photosense AS
Cartilla AS
Other fine chemicals
Norwegian Antibodies AS
Reumatech AS
PlasmAcute AS
Denomaga Nutritional Lipids AS
Aqua Bio Technology AS
Unitargeting Research AS
Santosolve AS
Predimed AS
EWOS Innovation
Biotec Pharmacon ASA
siRNAsense AS
Telelab AS
Eximo AS
Eximo AS
Spermatech AS
Tipogen AS
Maritex AS
Hepmarin AS
Thia Medica AS
Pharmaceutical
Norferm DA
Marine Bioproducts AS
Drug delivery
Alpharma AS
Probio Group AS
CancerCure AS
GE Healthcare
Promar AS
Inovio AS
Nycomed Pharma AS
Scalpro AS
Optinose AS
Weifa AS
Scanbio ASA
PCI Biotech AS
Norwegian life science companies;
a young sector limited by access to risk capital
Founding year
14
Total man-years 2004
90
13
12
12
80
11
10
10
10
70
10
60
8
8
50
6
6
40
4
4
4
4
3
30
20
2
10
0
0
<1985 1985- 1995
1994
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
A high risk – high reward business:
Biotech companies are usually capital
intensive and susceptible to international
financial trends.
0
<20
21-50
51-100
101-250
251-1000
>1000
Approximately half of the companies
have been established since 1999,
and more than 70% have less than
20 employees.
Norwegian biomedical companies 2004
KEY FIGURES 2004
Number of companies (medtech excluded)
48
Drug discovery or drug delivery companies
29
Companies with products in clinical development
11
Total man-years
3,200
Revenues 2004 (mill USD)
1,200
Industry investments in biotech R&D 2004 (mill USD)
> 150
ACADEMIC PARTNERSHIPS
Active academic research agreements 2004
93
Total new patent applications 2004
73
Joint patents with academia
11
INUSTRY PARTNERSHIPS
Total active business partners in 2004
91
New business partners in 2004
31
Industry partners - Scandinavia
8
Industry partners - other Europe
14
Industry partners - US and Canada
9
Since 2004:
• Several successful
venture rounds
• 3 IPOs
• 3 trade sales
The Norwegian drug discovery universe – examples:
Gemvax
Photocure
Marketed and pipeline
anti-cancer products
based on proprietary
photochemical process.
PCI
Targeted delivery of
cytostatics and DNA,
based on a photostimulation. In preclinic.
Clavis
Cancer vaccines based
on telomerase (phase II).
Acquired by Pharmexa
(Denmark) in 2005
Phase II clinical
program with novel
technology and device
for nasal drug delivery.
Lytix
Preclinical pipeline of
peptidomimetic drugs for
bacterial and fungal
infections, as well as cancer.
Immunotherapy and
vaccine technology based
on novel peptides.
Products in phase II.
Algeta
Phase II cancer radiotherapeutics based on
bone-seeking alphaemitters.
Affitech
Human recombinant
antibody therapeutics for
cancer. Preclinical pipeline
and several international
partnerships.
Clinical pipeline of anticancer drugs based on
novel liposome delivery.
Optinose
Bionor Immuno
Biotec
Pharmacon
Beta-glucans in phase
II as immunostimulant,
e.g. for diabetic ulcers
and enhancement of
anti-cancer antibodies
A-viral
Phase II immunomodulating
drug, indications include HIV,
cancer and autoimmune
diseases.
Lauras
Novel immunostimulatory
therapy for HIV/AIDS in
Phase II.
Biosergen
Novel anti-infectives,
including Nystatin
analogues. Research
phase.
Navamedic
Santosolve
Pharmaceutical grade
glucosamine-HCl approved
for osteoarthritis therapy.
Topically administered
pain-reliever based on
strontium. Phase II studies
ongoing.
Avexxin
Research phase antiinflammatory drug lead,
aiming for psoriasis
and RA.
The Norwegian drug discovery universe – examples:
Gemvax
Photocure
Marketed and pipeline
anti-cancer products
based on proprietary
photochemical process.
PCI
Targeted delivery of
cytostatics and DNA,
based on a photostimulation. In preclinic.
Clavis
Cancer vaccines based
on telomerase (phase II).
Acquired by Pharmexa
(Denmark) in 2005
Phase II clinical
program with novel
technology and device
for nasal drug delivery.
Lytix
Preclinical pipeline of
peptidomimetic drugs for
bacterial and fungal
infections, as well as cancer.
Immunotherapy and
vaccine technology based
on novel peptides.
Products in phase II.
Algeta
Phase II cancer radiotherapeutics based on
bone-seeking alphaemitters.
Affitech
Human recombinant
antibody therapeutics for
cancer. Preclinical pipeline
and several international
partnerships.
Clinical pipeline of anticancer drugs based on
novel liposome delivery.
Optinose
Bionor Immuno
Biotec
Pharmacon
Beta-glucans in phase
II as immunostimulant,
e.g. for diabetic ulcers
and enhancement of
anti-cancer antibodies
A-viral
Phase II immunomodulating
drug, indications include HIV,
cancer and autoimmune
diseases.
Lauras
Novel immunostimulatory
therapy for HIV/AIDS in
Phase II.
Biosergen
Novel anti-infectives,
including Nystatin
analogues. Research
phase.
Navamedic
Santosolve
Pharmaceutical grade
glucosamine-HCl approved
for osteoarthritis therapy.
Topically administered
pain-reliever based on
strontium. Phase II studies
ongoing.
Avexxin
Research phase antiinflammatory drug lead,
aiming for psoriasis
and RA.
Biomedical public–private partnerships
OSLO
The Radium Hospital
11
http://radium.no
The National Hospital
11
www.rikshospitalet.no
University of Oslo
7
www.uio.no
Norwegian Instute for Public Health
5
www.fhi.no
Ullevål University Hospital
4
www.ulleval.no
Veterinary Collage of Norway
2
www.veths.no
Akershus University Hospital
1
www.ahus.no
Norwegian University for Life Sciences (at Ås)
1
www.umb.no
Forsvarets Mikrobiologiske Institutt - Research Institute
1
Aker University Hospital
0
www.aus.no
1
www.uis.no
University of Bergen
5
www.uib.no
Haukeland University Hospital
2
www.helse-bergen.no
Numbers indicate how
many Norwegian
biomedical companies
cooperate with a given
academic institution
Tromsø
STAVANGER
University of Stavanger
BERGEN
Trondheim
Bergen
TRONDHEIM
SINTEF - Research Institute
6
www.sintef.no
NTNU - Norwegian University of Science and Technology
3
www.ntnu.no
St. Olavs' Hospital - Trondheim University Hospital
1
www.stolav.no
University Hospital Northern Norway
4
www.unn.no
University of Tromsø
3
http://uit.no
Fiskeriforskning - Research Insitute
1
www.fiskeriforskning.no
TROMSØ
Oslo
Stavanger
Areas of focus;
the life science base for an emerging industry
1. Human medicine: From biobanks to clinical development
 Attract industry to technology platforms designed to maximize synergies
between biobanks – bioinformatics – functional genomics – clinical
development.
2. Blue-Green breeding: Safe quality-food from healthier animals
 Utilize methodological synergies between human and veterinary biobanks
in order to maintain an edge in fish/livestock health and product quality.
3. Marine bioprospecting: Be in the forefront of an omnipotent field
 Expand our harvest from the sea to sophisticated high-value products with
applications in food, feed, ingredients, processes and medicines.
4. Environmental biotech: Spearhead development
 Products and services for pollution control, waste clean-up and
environment-friendly industry processes, particularly related to the
energy sector.
Synergy along the biomedical value chain
NATIONAL
STORAGE
FUGE: BIOINFORMATICS
BIOPROSPECTING
AUTOMATED
PICKING
FUGE:
GENOMICS
MEDICINAL
CHEMISTRY
MICROTITER
ALIQUOTS
FUGE:
PROTEOMICS
Biobank
Targets
Drug
discovery
PHARMACOGENOMICS
Clinical
development
MARKETING AND BUSINESS DEVELOPMENT
A coherent research and industry policy
t1
idea
business
plan
Seed funds
VC round 1
t2
t3
startup
VC round 2/3
market
player
t4
profitable
• Identify uniqueness
and potential
• Recruit excellent
management
• Product
development
• Contracts and
product sale
• Protect intellectual
property
• Technology
validation
• Commercial
partnerships
• Exit for venture
investors
Technology and
product development
Business
development
Technology platforms
and explorative
research
Proof of principle
studies
A coherent research and industry policy
t1
idea
business
plan
Seed funds
VC round 1
t2
t3
startup
VC round 2/3
market
player
t4
profitable
• Identify uniqueness
and potential
• Recruit excellent
management
• Product
development
• Contracts and
product sale
• Protect intellectual
property
• Technology
validation
• Commercial
partnerships
• Exit for venture
investors
OFU & IFU
contracts
INT &
Fast track
FUGE
Individual Grants
Centres of Excellence
FORNY
BIA grants
SFI
Innovation Norway;
the health and biotech sector strategy
1.
Strategy development: NorBioBase as a proactive instrument for
Innovation Norway and the Research Council, as well as an efficacy
measure for sector policies.
2.
National profiling: Based on the database, increase visibility of the
Norwegian life science sector and develop a profile consistent with the
main research priorities and the actual strengths of the industry sector.
3.
Support companies: Use this database to identify the companies with
a) highest synergy to other key Norwegian sectors and b) the highest
success potential, – and offer them 2-3 years support related to product
and business development.
4.
Reinforce the TTOs: Act as an international extension of the university
tech-transfer offices, identifying potential licensees and management
resources for new start-ups.
5.
Value chain perspective: Support business development activities
related to the national technology platforms, i.e. functional
genomics/biobanks (FUGE), bioprospecting (MabCent) and the new
Centers for Research-Driven Innovation (SFI).